InvestorsHub Logo
Followers 5
Posts 1418
Boards Moderated 0
Alias Born 11/10/2015

Re: mickyboy59 post# 55673

Monday, 04/29/2019 10:40:25 AM

Monday, April 29, 2019 10:40:25 AM

Post# of 58854
From the Avectas site

About Avectas
Avectas is a cell engineering technology business, enabling the manufacture of cell therapies. Avectas’ technology, Solupore®, delivers advanced molecules such as mRNA, proteins and gene editing tools to a range of primary cell types including T cells for immuno-oncology and gene editing applications. Solupore® utilizes a membrane disruptive approach to rapidly deliver advanced molecules to cells. It is a simple, rapid and gentle process that yields superior engineered cells. Solupore® results in improved cell processing times and cell health relative to viral vectors and electroporation, leading to a more cost-effective manufacturing process. Avectas is currently partnering with immuno-oncology and gene editing businesses to deliver their proprietary molecules. Avectas is also seeking therapeutic molecules to in-license as the core of a therapeutic program.

[color=red][/color]Our vision is to become the gold standard in vector-free intracellular delivery.[color=red][/color]



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APDN News